Conference Coverage

VIDEO: Consider chikungunya for unexplained seronegative arthritis


 

EXPERT ANALYSIS FROM ANNUAL PERSPECTIVES IN RHEUMATIC DISEASES

References

LAS VEGAS – When rheumatologists consider a differential diagnosis that includes seronegative rheumatoid arthritis, they should also consider chikungunya, according to Len Calabrese, DO.

The patient who presents with weeks to months of unexplained arthralgia and perhaps arthritis and a negative autoimmune panel deserves consideration of chikungunya or another arbovirus, said Dr. Calabrese, speaking at the annual Perspectives in Rheumatic Diseases held by the Global Academy for Medical Education.

Among the mosquito-borne arboviruses now in play in the Western Hemisphere, chikungunya is particularly likely to cause long-lasting and sometimes debilitating joint pain weeks and even months after initial infection.

An alphavirus, chikungunya virus makes most affected individuals quite ill, and serum IgG and IgM titers persist long after infection. Testing is straightforward, as long as the virus is a candidate diagnosis, Dr. Calabrese said.

In addition to obtaining an accurate travel history, said Dr. Calabrese, physicians should consider the possibility of autochthonous transmission, which occurs when an infected individual who returns from an endemic area is bitten by mosquitoes once home. Flares of autochthonous transmission can result in pockets of locally heavy transmission far from the zones where chikungunya usually resides.

Dr. Calabrese is chair of clinical immunology and chair of osteopathic research and education at the Cleveland Clinic, and he reported no relevant financial disclosures.

Global Academy for Medical Education and this news organization are owned by the same parent company.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

koakes@frontlinemedcom.com

On Twitter @karioakes

Recommended Reading

FDA’s arthritis advisory committee unanimously backs biosimilar Humira
MDedge Internal Medicine
FDA advisory panel unanimously backs biosimilars for Humira, Enbrel
MDedge Internal Medicine
Abatacept autoinjector approved to treat rheumatoid arthritis
MDedge Internal Medicine
RISE registry stockpiles U.S. rheumatology data
MDedge Internal Medicine
RA patients report worse symptoms at diagnosis, despite earlier presentation
MDedge Internal Medicine
Hemophilia carriers are at risk for abnormal bleeding
MDedge Internal Medicine
Biosimilar version of etanercept gains FDA approval
MDedge Internal Medicine
Lowering LDL-C yields usual benefits in rheumatoid arthritis
MDedge Internal Medicine
Simtuzumab did not help IPF patients
MDedge Internal Medicine
Try non-TNF biologics for RA if anti-TNF fails
MDedge Internal Medicine